| Keywords: |
cancer survival; disease-free survival; survival rate; gene mutation; clinical trial; fatigue; bevacizumab; cisplatin; cytotoxic agent; cancer combination chemotherapy; cancer risk; risk benefit analysis; gemcitabine; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; cancer staging; drug megadose; recurrence risk; antineoplastic agent; letter; gene overexpression; carboplatin; gene expression profiling; lung non small cell cancer; nausea; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; excision repair cross complementing protein 1; risk assessment; docetaxel; rna; drug fatality; microarray analysis; ras protein; age distribution; pharmacogenetics; navelbine; drug dose regimen; epidermal growth factor receptor kinase inhibitor; drug indication
|
